DOCSLIB.ORG

Novel Method of Administering Β-Blockers and Novel Dosage Forms Containing Same Anwar A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Method of Administering Β-Blockers and Novel Dosage Forms Containing Same Anwar A University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 1-31-1984 Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same Anwar A. Hussain University of Kentucky Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Hussain, Anwar A., "Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same" (1984). Pharmaceutical Sciences Faculty Patents. 124. https://uknowledge.uky.edu/ps_patents/124 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Unlted States Patent [191 [11] 4,428,883 Hussain [45] Jan. 31, 1984 [54] NOVEL METHOD OF ADMINISTERING 4,012,444 3/l977 Lunts ................................. .. 424/ 324 B-BLOCKERSF0 RMS Co NTA' AND, INING NOVEL SAME DOSAGE ' 4,250,163, , 1.1’;2/l981 llieoll’loldNagaioe a ......................................... ---- -~.. .. 424/14 [7 5 ] I nventor : An war A . Hussam,° Lexington' , Ky . FOREIGN PATENT DOCUMENTS [73] Assignee: The University of Kentucky Research . Foundation’ Lexington, Ky. 979389 1/ 1965 United Klngdom . I [21] APPL Nod 241,413 OTHER PUBLICATIONS . Stern, Arzmit. Forsch, vol. 24, 1974, pp. 70-71. [22] Flled‘ Mm‘- 6’ 1981 Black, Brit. J. PharmacoL, (1965) 25, pp. 577-591. [51] Int. Cl.3 ................... .. A61K 27/00; A61K 31/15; Prima'y Examiner_stanley L Friedman A61K 31/40; A61K 31/47; A61K 31/135; Attorney, Agent, or Firm-Burns, Doane, Swecker & A61K 31/165; A61K 31/435; A61K 31/475; Mathis A61K 47/00; C07C 143/90; CllD 1/28; C09F - 5 /()() [57] ABSTRACT [52] US. Cl. .......................... .. 424/248.5l; 260/ 404.5; The invention provides a novel method of administep 260/401; 424/256; 424/258; 424/262; 424/274; ing selected known adrenergic B-receptor blocking ‘ 424/324; 424/327; 424/330; 424/358; 424/362 agents, such as dichloroisoproterenol, pronethalol, sota [58] Field of Search ..................... .. 424/ 14, 28, 34, 39, 101 and alprenolol, which are of use in the treatment of 424/230{ 24851’ 274’ 324’ 358’ 362; 260/501], angina pectoris, arrhythmias, hypertension and other 404-5 A’ 401 S’ 324’ 248'51, 262’ 256’ 258’ 327’ cardiac conditions, and migraine. The invention further 330, 274, 358, 362 provides novel dosage forms of those B-blockers which [56] References Cited an; adapted for nasal adniinistcrlatiorti andtwhich include us. PATENT DOCUMENTS so1n,ses1n,u o S s“ p n o s ge 5 an ° imn.n e 8 3,676,493 7/ 1972 Smith ......................... .. 260/4045 R 61 Claims, No Drawings 4,428,883 1 2 ride, alprenolol hydrochloride, metoprolol tartrate, NOVEL METHOD OF ADMINISTERING nadoxolol hydrochloride, pamatolol sulfate, timolol B-BLOCKERS AND NOVEL DOSAGE FORMS CONTAINING SAME maleate, bupranolol hydrochloride, etc.); generally, the selected B-blocker is employed in the instant composi BACKGROUND OF THE INVENTION tions and method in the pharmaceutically acceptable 1. Field of the Invention form which has previously been found most advanta The present invention relates to a novel method of geous for oral or intravenous use. The structural formu administering selected known adrenergic B-receptor lae for the free bases encompassed by the present inven blocking agents, and to novel dosage forms containing 10 such agents adapted for nasal administration. tion are set forth below: 2. Background Art A number of B-adrenergic blocking agents are dichloroiso- OH known. Such agents are widely used therapeutically, ' proterenol Cl | chie?y in the management of hypertension and in the 15 treatment of angina pectoris, arrhythmias and other Cl nciicmNHcmcl-mz cardiac conditions, and also possibly in the treatment of migraine. Unfortunately, however, these known B pronethalol 0H blockers are inef?ciently and variably absorbed from oral dosage forms, probably because of extensive‘ me tabolism of the drug in the gastrointestinal tract and/or extensive effects of the ?rst pass through the liver. The present inventor and his co-workers have previ ously reported that one widely used B-blocker, pro sotalol (|)H v ’ pranolol, can be effectively administered in nasal dos CHgSOgNH-Q- CHCH2NHCH(CH3)2 age form. Nasal administration of propanolol has been found to provide enhanced bioavailability and mini mized variations in blood levels as compared to oral oxprenolol 0H administration. See copending Hussain et a1.‘ Applica OCH2CHCH2NHCH(CH3)2 tion Ser. No. 063,176, ?led Aug. 3, 1979; Hussain et al. J. Pharm. Sci., Vol. 68, No. 8, September, 1979, page OCH2CH=CH2 1196; Hussain et al, J. Pharm. Sci, Vol. 69, No. 10, October, 1980, page 1240; Hussain et al, J. Pharm. Sci, Vol. 69, No. 12, December, 1980, pages 1411-1413. pindolol Iii 35 N SUMMARY OF THE INVENTION Surprisingly, the present inventor has now found that yet other adrenergic B-receptor blocking agents can be effectively administered nasally. More speci?cally, the present inventor has found that selected B-blockers, 40 OCH2(‘:HCH2NHCH(CH3)2 which differ substantially in chemical structure from OH propanolol and which also have signi?cantly different biological pro?les [e.g., they may differ in potency, metoprolol I B-blocker receptor selectivity (B1 versus 3;), agonist cmocmcm-Q-ocr-lzcncnzNncmcnm properties and/ or membrane-stabilization activity] from OH that of propanolol, can nevertheless be advantageously formulated into novel nasal dosage forms and adminis nadoxolol , OH tered nasally to provide enhanced bioavailability and | /NH2 minimized variations in blood levels as compared to OCl-I2CHCH2C\ oral dosage forms of those B-blockers, while at the same . \Non time providing relative ease of administration when compared to the intravenous route. The novel nasal dosage forms of the invention can be solutions, suspen practolol (IJH sions, ointments or gels adapted for nasal administra tion. 55 (Cl-I3)2CHNHCH2CHCH20—©—NI-I?CH; DETAILED DESCRIPTION OF THE O INVENTION butoxamine CH3 The selected B-blockers for use in the compositions HOCHCHNI-IC(CH3)3 and methods of the present invention are dichloroiso 60 proterenol (DCI), pronethalol, sotalol, oxprenolol, pin OCH3 dolol, metoprolol, nadoxolol, practolol, butoxamine, alprenolol, metalol, nifenalol, acebutolol, atenolol, CH3O bunolol, carteolol, labetalol, pamatolol, timolol, ti alprenolol prenolol, xipranolol and bupranolol. Any pharmaceuti 65 cally acceptable form of these B-blockers can be em ployed, i.e. the free base ora pharmaceutically accept OH able salt or ester thereof (e.g., oxprenolol hydrochlo 4,428,883 3 4 -continued -continued xipranolol metalol OH CH3 CH(|3HNHCH3 ' 5 H1? CH3 OH SOZCH3 ocmcncnmncmcm); nifenalol (IJH ’ i 10 O2N—©—CHCH1NHCH(CH3)2 CH3 acebutolol . bupranolol H3O cocn; l5 CH3CH2CH2CONH OCH7_(l3HCH2Nl-ICH(CH3)2 0H ' 20 These B-blockers can be made by well-known methods. atenolol (‘H-I In accord with the present invention, the selected 0CH1CHCH2NHCH(CH3)2 ,B-blockers named supra can be administered nasally with results considerably superior to those obtained with oral administration in terms of enhanced drug 25 bioavailability and minimization of blood level varia CHZCONHZ tions, thus enabling use of these B-blockers at lower dosage levels than was previously possible except in the bunolol (|)l-_l case of intravenous administration. It would appear that these selected B-blockers are rapidly absorbed from the CED-ocmcncnmnqc?a); 30 nasal mucosa into systemic blood without ?rst-pass ll ' ‘ metabolism. > 0 Any of the selected B-blockers identi?ed above can be conveniently administered nasally to warm-blooded carteolol H animals by formulating it into a nasal dosage form com I 35 prising the desired B-blocker, in an effective B-blocking N ¢O amount, together with a nontoxic pharmaceutically acceptable nasal carrier therefor. As indicated earlier, the B-blocker can be employed in the form of the free base or in the form of a pharmaceutically acceptable salt 0CH2CHCH2NHC(CH3)3 40 or ester thereof. Suitable nontoxic pharmaceutically OH acceptable nasal carriers will be apparent to those skilled in the art of nasal pharmaceutical formulations. labetalol CoNm For those not skilled in the art, reference is made to the text entitled “REMINGTON’S PHARMACEUTI OH 45 CAL SCIENCES”, 14th edition, 1970. Obviously, the choice of suitable carriers will depend on the exact U-cmcmanmtcmancit; 0H nature of the particular nasal dosage form desired, e.g., whether the B-blocker is to be formulated into a nasal pamatolol OCH2CHCH2NHCH(CH3)2 50 solution (for use as drops or as a spray), a nasal suspen sion, a nasal ointment or a nasal gel. Preferred nasal OH dosage forms are solutions, suspensions and gels, which contain a major amount of water (preferably puri?ed CHgCI-IgNHCOOCI-Ig water) in addition to the active ingredient. Minor 55 amounts of other ingredients such as pH adjusters (e.g., a base such as NaOH), emulsi?ers or dispersing agents, timolol S N/ \N OH buffering agents, preservatives, wetting agents and jell I ing agents (e.g., methylcellulose) may also be present. / \ )I——-H—OCH2CHCH2NHC(CH3)3 Most preferably, the nasal composition is isotonic, i».e. it O N 60 has the same osmotic pressure as blood serum; If de sired, sustained release nasal compositions,‘ e.g. sus~ tained release gels, can be readily prepared, preferably by employingthe desired‘ B-blocker in 'one of its rela tiprenolol OH tively insoluble forms, such as the free base or an insolu? OCHZCHCHZNHCKKCHQZ ' ‘ 65 ble salt.v When the free base is not suf?ciently insoluble for sustained release compositions, or when a more : is-cn; highly insoluble form is desired, a long chain carboxylic acid salt of the desired B-blocker can be conveniently 4,428,883 5 6 employed.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • 33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline And
    J. Smooth Muscle Res. 33 : 99-106. 99 The )32 and [33-Adrenoceptor-Mediated Relaxation Induced by Isoprenaline and Salbutamol in Guinea Pig Taenia Caecum Katsuo KOIKE, Tsukasa IcHiNo, Takahiro HORINOUCHI and Issei TAKAYANAGI Departmentof Chemical Pharmacology, Toho University School of PharmaceuticalSciences, 2-2-1, Miyama,Funabashi, Chiba 274, Japan Abstract To understand the receptor subtypes responsible for /3adrenoceptormediated relaxa tion of guinea pig taenia caecum, we investigated the effects of isoprenaline and salbutamol . Isoprenaline and salbutamol caused dose-dependent relaxation of the guinea pig taenia caecum. Propranolol, bupranolol and butoxamine produced shifts of the concentration response curves for isoprenaline and salbutamol. Schild regression analyses carried out for propranolol against isoprenaline and salbutamol gave pA2 values of 8.43 and 8.88, respective ly. Schild regression analyses carried out for butoxamine against isoprenaline and sal butamol gave pA2 values of 6.46 and 6.68, respectively. Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 8.60 and 8.69, respectively. However, in the presence of 3 x 10' M atenolol, 10-4 M butoxamine and 10-6 M phentolamine to block the fir , /32 and a -adrenoceptor effects, respectively, Schild regression analyses carried out for bupranolol against isoprenaline and salbutamol gave pA2 values of 5.77 and 5.97, respectively. These results suggest that the relaxant responses to isoprenaline and salbutamol in the guinea pig taenia caecum are mediated by both the /.32 and the A-adrenoceptors. Key words : f2-adrenoceptor, A-adrenoceptor, isoprenaline, salbutamol , guinea pig taenia caecum Introduction The /3adrenoceptors were subclassified as and /32subtypes based on the agonist potency and tissue localization.
    [Show full text]
  • Relaxation Ofcat Trachea by 13-Adrenoceptor Agonists
    Br. J. Pharmac. (1983), 78,417-424 Relaxation of cat trachea by 13-adrenoceptor agonists can be mediated by both f3I- and 132-adrenoceptors and potentiated by inhibitors of extraneuronal uptake Stella R. O'Donnell & Janet C. Wanstall Pharmacology Section, Department of Physiology and Pharmacology, University of Queensland, St Lucia, Brisbane, Qld. 4067, Australia 1 Responses (relaxation) to the P-adrenoceptor agonists, isoprenaline, fenoterol or noradrenaline, were obtained on cat tracheal preparations contracted with a submaximal concentration of carbachol (0.5 JAM). 2 The relative potencies of isoprenaline: fenoterol: noradrenaline were 100:8.1:10.7. From this, it was concluded that responses were mediated predominantly by 131-adrenoceptors but that a minor population of P2-adrenoceptors might also be involved. 3 Schild plots for the selective antagonists atenolol (Pi1-selective) or ICI 118,551 (32-selective) were in different locations, i.e. were separated, depending on whether the antagonist was antagoniz- ing noradrenaline or fenoterol. This supported the conclusion that 12- as well as Pl-adrenoceptors were involved in mediating the response. In this respect, cat trachea resembles cat atria (rate responses). 4 In the presence of atenolol the concentration-response curves to fenoterol became biphasic. This was interpreted as indicating that the P2-adrenoceptors were too few in number to elicit a maximum tissue response. 5 Responses to isoprenaline of cat trachea were potentiated by the extraneuronal uptake inhibitor drugs, corticosterone and metanephrine. This indicated that extraneuronal uptake could modulate P-adrenoceptor-mediated responses (relaxation) of cat trachea. 6 Cat trachea resembles guinea-pig trachea in that (i) the P-adrenoceptor population mediating relaxation is mixed (PI + P2) and (ii) responses to isoprenaline are modulated by its extraneuronal uptake.
    [Show full text]
  • Effects Ofnew Beta-Blocking Agent Wolff-Parkinson-White Syndrome
    Br Heart J: first published as 10.1136/hrt.34.12.1272 on 1 December 1972. Downloaded from British Heart Journal, I972, 34) I272-I282. Effects of new beta-blocking agent (DL-tiprenolol) on conduction within normal and anomalous atrioventricular pathways in Wolff-Parkinson-White syndrome J. Roelandt, L. Schamroth, and P. G. Hugenholtz From the Thoraxcentre, University Hospital and Medical Faculty, Rotterdam, The Netherlands; and the Baragwanath Hospital and the University of the Witwatersrand, J7ohannesburg, South Africa The effects of DL-tiprenolol (DU 2I445) - a new beta-receptor blocking agent - and atropine on both normal and abnormal conduction pathways in the Wolff-Parkinson-White (WPW) syn- drome were studied by means of His bundle electrograms and atrial pacing. It was shown that DU 2I445 slows conduction through both pathways significantly (P, o os) and has a potential value in the treatment of symptomatic WPW syndrome and perhaps in other types of re-entrant tachycardias. The effects ofatropine were also studied in 2 patients. Atropine did not affect bypass conduction whereas A V conduction velocity was definitely increased. copyright. The study also shedsfurther light on the mechanism of WPW syndrome. It was found that the bypass had different conducting properties and was most probably a different conducting structure from the normal A V pathway. Surgical division of the anomalous pathway reason for a surgical approach, virtually as a in the Wolff-Parkinson-White (WPW) syn- measure of desperation. http://heart.bmj.com/ drome has recently been carried out with some Little is known about the conduction success in a few patients with incapacitating properties of, and the influence of drugs on, attacks of tachycardia (Cobb et al., I968; the anomalous bypass.
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]